🚀 VC round data is live in beta, check it out!
Diagnostyka Valuation Multiples
Discover revenue and EBITDA valuation multiples for Diagnostyka and similar public comparables like Vimian Group, SonoScape, Wandong Medical, Fleury and more.
Diagnostyka Overview
About Diagnostyka
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
Founded
N/A
HQ
Employees
7.0K
Website
Financials (LTM)
EV
$2B
Diagnostyka Financials
Diagnostyka reported last 12-month revenue of $701M and EBITDA of $179M.
In the same LTM period, Diagnostyka generated $179M in EBITDA and $82M in net income.
Revenue (LTM)
Diagnostyka P&L
In the most recent fiscal year, Diagnostyka reported revenue of $543M and EBITDA of $142M.
Diagnostyka expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $701M | XXX | $543M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $354M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $179M | XXX | $142M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $82M | XXX | $62M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $153M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Diagnostyka Stock Performance
Diagnostyka has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Diagnostyka's stock price is $49.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.1% | XXX | XXX | XXX | $1.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDiagnostyka Valuation Multiples
Diagnostyka trades at 2.8x EV/Revenue multiple, and 10.9x EV/EBITDA.
EV / Revenue (LTM)
Diagnostyka Financial Valuation Multiples
As of April 20, 2026, Diagnostyka has market cap of $2B and EV of $2B.
Equity research analysts estimate Diagnostyka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnostyka has a P/E ratio of 20.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.9x | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBIT | 15.9x | XXX | 21.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.5x | XXX | XXX | XXX |
| P/E | 20.5x | XXX | 26.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 24.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Diagnostyka Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Diagnostyka Margins & Growth Rates
Diagnostyka's revenue in the last 12 month grew by 14%.
Diagnostyka's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Diagnostyka's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diagnostyka's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Diagnostyka Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Diagnostyka Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diagnostyka | XXX | XXX | XXX | XXX | XXX | XXX |
| Vimian Group | XXX | XXX | XXX | XXX | XXX | XXX |
| SonoScape | XXX | XXX | XXX | XXX | XXX | XXX |
| Wandong Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Fleury | XXX | XXX | XXX | XXX | XXX | XXX |
| Butterfly Network | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnostyka M&A Activity
Diagnostyka acquired XXX companies to date.
Last acquisition by Diagnostyka was on XXXXXXXX, XXXXX. Diagnostyka acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Diagnostyka
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDiagnostyka Investment Activity
Diagnostyka invested in XXX companies to date.
Diagnostyka made its latest investment on XXXXXXXX, XXXXX. Diagnostyka invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Diagnostyka
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Diagnostyka
| Where is Diagnostyka headquartered? | Diagnostyka is headquartered in Poland. |
| How many employees does Diagnostyka have? | As of today, Diagnostyka has over 7K employees. |
| Is Diagnostyka publicly listed? | Yes, Diagnostyka is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Diagnostyka? | Diagnostyka trades under DIA ticker. |
| When did Diagnostyka go public? | Diagnostyka went public in 2025. |
| Who are competitors of Diagnostyka? | Diagnostyka main competitors are Vimian Group, SonoScape, Wandong Medical, Fleury. |
| What is the current market cap of Diagnostyka? | Diagnostyka's current market cap is $2B. |
| What is the current revenue of Diagnostyka? | Diagnostyka's last 12 months revenue is $701M. |
| What is the current revenue growth of Diagnostyka? | Diagnostyka revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Diagnostyka? | Current revenue multiple of Diagnostyka is 2.8x. |
| Is Diagnostyka profitable? | Yes, Diagnostyka is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diagnostyka? | Diagnostyka's last 12 months EBITDA is $179M. |
| What is Diagnostyka's EBITDA margin? | Diagnostyka's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Diagnostyka? | Current EBITDA multiple of Diagnostyka is 10.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.